A workflow to build PBTK models for novel species

Abstract

Physiology-based pharmacokinetic and toxicokinetic (PBPK/TK) models allow us to simulate the concentration of xenobiotica in the plasma and different tissues of an organism. PBPK/TK models are therefore routinely used in many fields of life sciences to simulate the physiological concentration of exogenous compounds in plasma and tissues. The application of PBTK models in ecotoxicology, however, is currently hampered by the limited availability of models for focal species. Here, we present a best practice workflow that describes how to build PBTK models for novel species. To this end, we extrapolated eight previously established rabbit models for several drugs to six additional mammalian species (human, beagle, rat, monkey, mouse, and minipig). We used established PBTK models for these species to account for the species-specific physiology. The parameter sensitivity in the resulting 56 PBTK models was systematically assessed to rank the relevance of the parameters on overall model performance. Interestingly, more than 80% of the 609 considered model parameters showed a negligible sensitivity throughout all models. Only approximately 5% of all parameters had a high sensitivity in at least one of the PBTK models. This approach allowed us to rank the relevance of the various parameters on overall model performance. We used this information to formulate a best practice guideline for the efficient development of PBTK models for novel animal species. We believe that the workflow proposed in this study will significantly support the development of PBTK models for new animal species in the future.

Metabolic profiling and in vitro-in vivo extrapolation of furathiocarb in mammalian hepatic microsomes

“…Without scientifically solid tools and procedures it is uncertain to translate in vivo and in vitro animal toxicological findings into human-relevant information. It is expected that interspecies differences, similar to the ones demonstrated in this paper and elsewhere, would be important inputs into physiologically-based toxicokinetic and toxicodynamic models [20] , [33] , [37] , [39] , [5] , [7] , [9] , in which species-selective toxic outcomes are modeled, interpreted and finally, hopefully, predicted and confirmed with targeted studies using new approach methodologies (NAMs) [32] .…”

A critical review of effect modeling for ecological risk assessment of plant protection products

“…Reproducibility is only one of the prerequisites for a crédible research (Wilkinson et al, 2016) and differently concerns materials, especially data (e.g., Rubach et al (2010); ; EFSA PPR Panel (2017)), methods and results (e.g., Tyne et al 2015) as described in papers. Focusing on model outputs, only few authors gave enough information for full reproducibility, given that some results cannot of course be exactly reproduced due to stochastic processes in the modelling approach (Carr and Belanger, 2019;Schneckener et al, 2020;.…”

The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development

“…It is anticipated that also in (neonatal and juvenile) pigs, PBPK models will be increasingly used to enhance the chance for successful development of PBPK models in equivalent human populations. Consistently, best practice guidelines for building PBPK models for ‘novel’ species (such as minipig) have very recently been proposed [ 99 ]. Specifically, for supporting the development of (mini)pig PBPK models, it is critical that the relevant physiological descriptors are available in sufficient detail.…”